Nexalin Technology (US:NXL) — Company Overview, News & Financial Data
Nexalin Technology develops non-invasive medical devices for addressing mental health disorders without pharmaceuticals.
About Nexalin Technology
Nexalin Technology (NASDAQ:NXL) is a company that specializes in developing advanced medical devices designed to address mental health and neuropsychiatric disorders without the use of pharmaceuticals. At the heart of its innovation is a non-invasive therapy technology, which aims at treating anxiety, depression, and insomnia through transcranial electrical stimulation. With a commitment to improving the standard of mental health care, Nexalin continues to invest in research and development to expand its product portfolio and reach. The company's objective is to offer effective, drug-free solutions for mental health conditions, making treatment accessible and reducing the stigma associated with traditional psychiatric medications.
Snapshot
Operations
Products and/or services of Nexalin Technology
- Research and development in Transcranial Electrical Stimulation technologies.
- Partnerships for clinical trials to validate and improve neuromodulation treatments.
- Manufacturing and distribution of FDA-cleared neuromodulation devices.
- Development of portable and user-friendly devices for home use.
- Expanding global reach through regulatory approvals in new markets.
Nexalin Technology executive team
- Mr. Mark WhitePresident, CEO & Director
- Dr. David Owens M.D.Chief Medical Officer, Member of Scientific Advisory Board & Director
- Ms. Carolyn SheltonExecutive VP of Clinical, Quality & Regulatory Affairs
- Mr. John Patrick ClaudeCo-Founder and Director of Engineering & Development
- Mr. Justin Van Fleet CPAChief Financial Officer